Background Patients with multiple sclerosis receiving ocrelizumab-treatment are in
desperate need of a protection against SARS-CoV-2 infection. Methods In this study …

Objectives Several concerns regard the immunogenicity of SARS-CoV-2 vaccines in people
with multiple sclerosis (pwMS), since the majority of them is treated with immunomodulating …

Background The COVID-19 epidemic raises important questions about the efficacy of
vaccines for people treated with ocrelizumab, an anti-CD20 therapy. Ocrelizumab has been …

Background Vaccination has proven to be effective in preventing SARS-CoV-2 transmission
and severe disease courses. However, immunocompromised patients have not been …

Importance B-cell–depleting therapies may affect the development of a protective immune
response following vaccination. Understanding the ability to develop vaccine-specific …

Objectives To evaluate whether a third vaccination shows an added effect on severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell responses in patients with multiple …

Objectives (1) To plot the trajectory of humoral and cellular immune responses to the primary
(two‐dose) COVID‐19 mRNA series and the third/booster dose in B‐cell‐depleted multiple …

Objective The objective of this study was to measure humoral responses after SARS-CoV-2
vaccination in MS patients treated with ocrelizumab (OCR) compared to MS patients without …

Introduction Since the development of the coronavirus disease (COVID-19) pandemic
caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), there has …

Background and purpose Although two doses of COVID‐19 vaccine elicited a protective
humoral response in most persons with multiple sclerosis (pwMS), a significant group of …